Biggest News Aggregation in the World
📰 Alvr News

Page 4 - Alvr News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Alvr. Real-time updates on events, politics, business and more.

AlloVir, Inc. (NASDAQ:ALVR) CEO Diana Brainard Sells 8,408 Shares

AlloVir, Inc. (NASDAQ:ALVR – Get Rating) CEO Diana Brainard sold 8,408 shares of the firm’s stock in a transaction on Wednesday, April 19th. The shares were sold at an average price of $3.71, for a total value of $31,193.68. Following the transaction, the chief executive officer now owns 921,164 shares of the company’s stock, valued […]
New York United States Diana Brainard Allovir Company Profile Securities Exchange Commission Denali Advisors

Short Interest in Independent Bank Co. (NASDAQ:IBCP) Rises By 10.9%

AlloVir, Inc. (NASDAQ:ALVR – Get Rating) CEO Diana Brainard sold 8,408 shares of the stock in a transaction dated Wednesday, April 19th. The stock was sold at an average price of $3.71, for a total transaction of $31,193.68. Following the transaction, the chief executive officer now owns 921,164 shares in the company, valued at $3,417,518.44. […]
Diana Brainard Allovir Inc Morgan Stanley Ensign Peak Advisors Inc Nisa Investment Advisors Swiss National Bank

AlloVir, Inc. (NASDAQ:ALVR) Short Interest Up 6.8% in March

AlloVir, Inc. (NASDAQ:ALVR – Get Rating) was the recipient of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 5,790,000 shares, an increase of 6.8% from the February 28th total of 5,420,000 shares. Based on an average daily trading volume, of 275,300 shares, the […]
Diana Brainard Vikas Sinha Allovir Inc Denali Advisors Morgan Stanley Allovir Company Profile

AlloVir, Inc. (NASDAQ:ALVR) Short Interest Update

AlloVir, Inc. (NASDAQ:ALVR – Get Rating) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 5,790,000 shares, a growth of 6.8% from the February 28th total of 5,420,000 shares. Based on an average trading volume of 275,300 shares, the short-interest […]
Diana Brainard Vikas Sinha Allovir Inc Nisa Investment Advisors Securities Exchange Commission Swiss National Bank

AlloVir (NASDAQ:ALVR) & Gilead Sciences (NASDAQ:GILD) Critical Comparison

AlloVir (NASDAQ:ALVR – Get Rating) and Gilead Sciences (NASDAQ:GILD – Get Rating) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability. Institutional & Insider Ownership 78.7% of Gilead Sciences shares are owned […]
United States Michaell Riordan Complera Eviplera Viracyte Inc Gilead Sciences Gilead Sciences Inc
Source: wkrb13.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

AlloVir, Inc. (NASDAQ:ALVR) Insider Beek Jeroen B. Van Sells 15,262 Shares

AlloVir, Inc. (NASDAQ:ALVR – Get Rating) insider Beek Jeroen B. Van sold 15,262 shares of the stock in a transaction on Tuesday, May 17th. The shares were sold at an average price of $4.40, for a total value of $67,152.80. Following the completion of the transaction, the insider now directly owns 389,526 shares in the […]
United States Beek Jeroenb Van Morgan Stanley Zacks Investment Research Blackrock Inc Allovir Inc

AlloVir (NASDAQ:ALVR) Lowered to Sell at Zacks Investment Research

AlloVir (NASDAQ:ALVR – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Monday, Zacks.com reports. According to Zacks, “AlloVir, Inc. is a late clinical-stage cell therapy company which focus on restoring natural immunity against life-threatening viral diseases. AlloVir, Inc. is based in […]
United Kingdom United States David Hallal Jeffreys Bornstein Allovir Inc Morgan Stanley

AlloVir (NASDAQ:ALVR) Upgraded by Zacks Investment Research to "Hold"

Zacks Investment Research upgraded shares of AlloVir (NASDAQ:ALVR – Get Rating) from a sell rating to a hold rating in a research report released on Tuesday, Zacks.com reports. According to Zacks, “AlloVir, Inc. is a late clinical-stage cell therapy company which focus on restoring natural immunity against life-threatening viral diseases. AlloVir, Inc. is based in […]
United States United Kingdom David Hallal Beek Jeroenb Van Allovir Inc Morgan Stanley

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science